Incretin & metabolic research compounds
Mazdutide
Also known as IBI362 · LY3305677 · Xinermei
A once-weekly dual GLP-1 / glucagon-receptor agonist, first approved in China in 2025.
In 60 seconds
Approved in China (2025) for weight management; phase 3 trials in obesity and type 2 diabetes, including a head-to-head versus dulaglutide. Trials report gastrointestinal events as most common; phase 1b work explored higher doses for tolerability.
- A phase 3 placebo-controlled trial measured weight change with mazdutide in Chinese adults.
- Summarises the development milestones leading to mazdutide’s first approval.
- A phase 3 trial compared mazdutide with dulaglutide in type 2 diabetes.
Mechanism
Like survodutide, mazdutide combines GLP-1 receptor agonism with glucagon-receptor agonism, the latter studied for energy expenditure and liver fat.
Research status
Approved in China (2025) for weight management; phase 3 trials in obesity and type 2 diabetes, including a head-to-head versus dulaglutide.
Key studies
A phase 3 placebo-controlled trial measured weight change with mazdutide in Chinese adults.
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight — N Engl J Med, 2025 · PMID 40421736
Summarises the development milestones leading to mazdutide’s first approval.
Mazdutide: First Approval — Drugs, 2025 · PMID 41028652
A phase 3 trial compared mazdutide with dulaglutide in type 2 diabetes.
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes — Nature, 2026 · PMID 41407860
A phase 1b trial explored the safety and efficacy of higher mazdutide doses.
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial — EClinicalMedicine, 2022 · PMID 36247927
Safety signals in the literature
Trials report gastrointestinal events as most common; phase 1b work explored higher doses for tolerability.
Legal status (South Africa)
Approved incretin medicines are prescription-only (scheduled) in South Africa and available only through a prescriber; research-grade material is not a medicine and is not for human use.
Related compounds we stock
Not stocked yet — get notified
Tell us you want Mazdutide and we’ll email you if we add it. Requests decide what we source next.
Not stocked yet
Get notified when we add Mazdutide
One email, only when it reaches the catalogue. Every request is counted when we choose what to stock next.
Comparisons
Questions
What is Mazdutide?
A once-weekly dual GLP-1 / glucagon-receptor agonist, first approved in China in 2025. Like survodutide, mazdutide combines GLP-1 receptor agonism with glucagon-receptor agonism, the latter studied for energy expenditure and liver fat.
What is the research status of Mazdutide?
Approved in China (2025) for weight management; phase 3 trials in obesity and type 2 diabetes, including a head-to-head versus dulaglutide.
What safety signals are reported for Mazdutide?
Trials report gastrointestinal events as most common; phase 1b work explored higher doses for tolerability.
Does Living Water Labs stock Mazdutide?
Not at present. Mazdutide is profiled here for reference, with citations to the published literature. You can ask to be notified if we add it. Approved incretin medicines are prescription-only (scheduled) in South Africa and available only through a prescriber; research-grade material is not a medicine and is not for human use.
More in Incretin & metabolic
Research reference only. This page summarises published literature; it is not medical advice and contains no guidance on human use. Products supplied by Living Water Labs are for laboratory research only.
